You just read:

Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin), Including Preliminary Results from TOUR™ Observational Patient Registry, at 2017 ECCMID Conference

News provided by

Theravance Biopharma, Inc.

Apr 18, 2017, 08:05 ET